Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis

Jasvinder A. Singh 1,2,3,4*, Alomgir Hossain 5, Ahmed Kotb 5 and George Wells 5

Abstract

Background: To perform a systematic review and network meta-analysis (NMA) to compare the risk of serious infections with immunosuppressive medications and glucocorticoids in lupus nephritis.

Methods: A trained librarian performed two searches: (1) PubMed for all lupus nephritis trials from the end dates for the systematic review for the 2012 American College of Rheumatology (ACR) lupus nephritis treatment guidelines and the 2012 Cochrane Systematic Review on treatments for lupus nephritis, to September 2013; and (2) PubMed and SCOPUS for all lupus trials (excluding lupus nephritis) from inception to February 2014, to obtain additional trials for harms data in any lupus patient. The search was updated to May 2016. Duplicate title/abstract review and duplicate data abstractions by two abstractors independently was performed for all eligible studies, including those studies abstracted for the 2012 ACR lupus nephritis treatment guidelines and the 2012 Cochrane Systematic Review on lupus nephritis treatments. We performed a systematic review and a Bayesian NMA, including randomized controlled trials (RCTs) of immunosuppressive drugs or glucocorticoids in patients with lupus nephritis assessing serious infection risk. Markov chain Monte Carlo methods were used to model 95% credible intervals (CrI). Sensitivity analyses examined the robustness of estimates.

Results: A total of 32 RCTs with 2611 patients provided data. There were 26 two-arm, five three-arm, and one four-arm trials. We found that tacrolimus was associated with significantly lower risk of serious infections compared to glucocorticoids, cyclophosphamide (CYC), mycophenolate mofetil (MMF), and azathioprine (AZA) with odds ratios (95% CrI) of 0.33 (0.12–0.88), 0.37 (0.15–0.87), 0.340 (0.18–0.81), and 0.32 (0.12–0.81), respectively. Conversely, CYC low dose (LD), CYC high dose (HD), and HD glucocorticoids were associated with higher odds of serious infections compared to tacrolimus, ranging from 4.84 to 12.83. We also found that MMF followed by AZA (MMF-AZA) was associated with significantly lower risk of serious infections as compared to CYC LD, CYC HD, CYC-AZA, or HD glucocorticoids with odds ratios (95% CrI) of 0.09 (0.01–0.76), 0.07 (0.01–0.54), 0.14 (0.02–0.71), and 0.03 (0.00–0.56), respectively. Estimates were similar to pair-wise meta-analyses. Sensitivity analyses that varied estimate (odds ratio vs. Peto’s odds ratio), method (random vs. fixed effects model), data (sepsis vs. serious infection data; exclusion of observational studies), treatment grouping (CYC and CYC HD as a combined treatment group vs. separate), made little/no difference to these estimates.

Conclusions: Tacrolimus and MMF-AZA combination were associated with lower risk of serious infections compared to other immunosuppressive drugs or glucocorticoids for lupus nephritis. In conjunction with comparative efficacy data, these data can help patients make informed decisions about treatment options for lupus nephritis.

(Continued on next page)
Background

Lupus nephritis is successfully treated with immunosuppressive drugs and glucocorticoids [1]. The benefits of these lupus treatments are well known with well-documented improved renal survival and function as well as reduced mortality with treatment [2–4]. A key concern for patients with lupus is the risk of infections (including serious infections) with immunosuppressive drugs and glucocorticoids, since both treatments suppress the immune system [5–7]. This concern likely plays a significant role in a patient’s decision regarding whether to take these medications, and how long to continue treatment, sometimes despite a strong physician recommendation.

Whether the risk of serious infections differs by the type of medication in lupus nephritis is unknown and controversial. A meta-analysis of treatments for lupus nephritis showed that the risk of major infection was not higher with cyclophosphamide (CYC) or azathioprine (AZA) plus glucocorticoids versus glucocorticoids alone [8]. In another meta-analysis, mycophenolate mofetil (MMF) was associated with a lower risk of overall infections compared with CYC, with a risk ratio of 0.65 [9]. On the other hand, a more updated and comprehensive 2012 Cochrane systematic review on lupus nephritis treatments showed that MMF was not associated with any significantly different risk of major infections (defined as infections other than herpes zoster) compared to intravenous CYC (the relative risk was 1.11 (95% confidence interval, 0.74–1.68)) [10, 11]. The findings from these meta-analyses differ due to differences in inclusion criteria, outcome (major infection vs. overall infection) and comparisons. Published meta-analyses, although methodologically sound, suffer from several limitations: (1) comparisons of most drugs were based on a few studies in most cases, thus making them potentially underpowered; (2) some studies included in meta-analyses analyzed major/serious infections while others analyzed all infections, combining these likely led to heterogeneity within such comparisons and also differences between meta-analyses; and (3) indirect comparisons between medications were not performed where head-to-head studies were not available. Lumley et al. [12] described network meta-analysis (NMA) as a way for indirect comparisons of treatments, where head-to-head trials are lacking.

Our aim was to overcome these challenges and conduct a state-of-the-art analysis. We therefore, performed a systematic review, meta-analysis and NMA of all lupus nephritis trials to date to compare the risk of serious infections with immunosuppressive and glucocorticoid treatment in lupus nephritis.

Methods

Systematic review methods

We conducted this systematic review and NMA based on the AHRQ recommendations [13] and the Cochrane handbook [14], and reported it according to the PRISMA guidelines [15]. No Institutional Review Board approval was needed since the study included only analyses of published data. The study protocol was registered in PROSPERO, CRD42016032965 (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016032965). We used the Cochrane systematic review [10], as well as the systematic review conducted for the American College of Rheumatology guidelines for treatment of lupus nephritis [16], to identify eligible studies. Searches were updated to September 2013 to identify additional studies using PubMed (Additional file 1: Appendix 1A); the search was updated to May 2016. We considered using harms data related to medications from any lupus randomized controlled trial (RCT), not just from lupus nephritis RCTs, by using a search in PubMed and SCOPUS from inception to February 2014 (Additional file 1: Appendix 1B). Examination of the data from this search revealed little additive data for harms for most outcomes of interest (16 RCTs; most had no usable data). Therefore, we determined that the advantage of inclusion of these data was outweighed by the disadvantage of increasing heterogeneity of patient population (from lupus nephritis to lupus). We included RCTs or controlled clinical trials for lupus nephritis that contained the common immunosuppressive drugs including CYC, MMF, AZA, cyclosporine (CSA), tacrolimus (TAC), rituximab (RTX), or glucocorticoids as one of the comparators. Belimumab studies could not be included in this systematic review since these studies excluded patients with active lupus nephritis and a Cochrane systematic review of belimumab for lupus is underway [17]. There were no restrictions with regard to dosage or duration of intervention. We limited our search to the English language. The PICO (Patient, Intervention, Comparator, Outcome) were defined as follows:

P: Adults 18 years or older, meeting the 1987 American College of Rheumatology Classification criteria for SLE [18] with lupus nephritis.
I: Interventions were immunosuppressant alone or in combination with other immunosuppressant or biologics (such as RTX) or corticosteroid. Medication doses were categorized as low, standard, or high dose.
C: Placebo or another immunosuppressant with/without biologic, at any dose of these medications.
O: Serious infections, defined as any of the following: serious infection, major infection, severe infection, sepsis, or bacterial infection. We refer to these as serious infection from here onwards.

Two trained abstractors independently reviewed abstract and title in duplicate (AO, AB) and selected articles for full PDF download. Two independent abstractors (AO, AB) abstracted all the data in duplicate and entered it directly into Microsoft excel sheets, which were pre-piloted for data abstraction. Another research associate checked the data for accuracy (AM). Studies were abstracted for this analysis if they included adults with lupus nephritis, one of the immunosuppressant drugs or glucocorticoids, and reported serious infection. An adjudicator (JS) resolved any disagreements not resolved by consensus.

Two reviewers (AO, JS) assessed the risk of bias according to the Cochrane risk of bias tool [19], examining the domains of randomization sequence generation, allocation sequence concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data (primary outcome data reporting, dropout rates and reasons for withdrawal, appropriate imputation of missing data, an overall completion rate ≥ 80 %), and selective outcome reporting and other potential threats to validity (considering external validity, e.g., relevant use of co-interventions, bias due to funding source). Each criterion was explicitly judged as follows: Yes = low risk of bias; No = high risk of bias; Unclear = either lack of information or uncertainty about potential for bias. We resolved any disagreements with consensus. We planned funnel plots to assess publication bias.

Pair-wise meta-analysis was conducted when data were sufficiently clinically and statistically homogeneous. We calculated the mean difference (MD) for the continuous and relative risk (RR) or Peto odds ratio (OR) (for rare events), for the dichotomous data. Heterogeneity of data was assessed by using the $\chi^2$ test, with a $P$ value < 0.10 indicating significant heterogeneity, and the $I^2$ statistic [20], with values > 50 % indicating substantial heterogeneity.

NMA methods
We conducted Bayesian mixed treatment comparison (MTC) meta-analyses. We used the WinBUGS software (MRC Biostatistics Unit, Cambridge, UK) to conduct Bayesian MTC meta-analysis using a binomial likelihood model that allows inclusion of multi-arm trials [21, 22]. We used the random-effects network meta-analyses as a conservative approach, since we anticipated some heterogeneity in study populations. We assessed the model fit and chose the model based on the assessment of the deviance information criterion (DIC) and the comparison of residual deviance to the number of unconstrained data points [21, 23]. We assigned vague priors, such as $N(0, 100^2)$, for basic parameters throughout [21] and informative priors for the variance parameter based on Turner et al. [24]. To ensure convergence was reached, trace plots and the Brooks-Gelman-Rubin statistic were assessed [25]. Three chains were fit in WinBUGS for each analysis, with 40,000 iterations, and a burn-in of 40,000 iterations [25, 26]. We calculated point estimates and 95 % credible intervals (CrI) for OR using the Markov Chain Monte Carlo methods. In order to check the consistency of the NMA results, we conducted the inconsistency analysis and constructed an inconsistency plot, and compared these results with our NMA results based on consistency model [27]. Heterogeneity of data was assessed by using the Tau-squared test, which examines heterogeneity due to study and study–drug interaction (smaller values indicate a better model). There is no specific range for this measure.

Both MTC and traditional meta-analysis require studies to be sufficiently similar in order to pool their results. To further investigate heterogeneity, where warranted, subgroup analyses and meta-regressions [22, 28] were considered. One subgroup analysis we planned was the comparison of estimates before and after 2004 considering potential change in management after the publication of the Contreras et al. [29] study in the New England Journal of Medicine. We considered other subgroup analyses by age, gender, race, and prior immunosuppressive therapy for lupus nephritis prior to the current episode, if data were available.

Graphical aids, in the form of network diagrams, were considered for NMA. We compared the NMA results to pair-wise meta-analyses where possible. We performed sensitivity analyses by using OR versus Peto’s OR for estimation. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the quality of direct evidence from meta-analysis versus estimates from the NMA, assessing indirectness, imprecision, inconsistency, risk of bias, publication bias, and other factors [30].

Several sensitivity analyses were conducted to test the robustness of main NMA findings, including (1) random versus fixed effects model, (2) the use of sepsis versus serious infection data from Appel et al. [31], (3) the exclusion of data from two observational studies previously included in the 2012 Cochrane review versus inclusion of all studies, and (4) comparing other medications to CYC and CYC high dose as a group versus separately. We
conducted sensitivity analyses based on different priors [32] and compared the parameter estimates (i.e., OR (95 % CrI)) and model fit criteria such as DIC and residual deviance with these priors to the main analysis.

**Results**

**Study cohort characteristics**

A total of 32 RCTs with 2611 patients met inclusion criteria and provided data for serious infections (Fig. 1). Detailed study characteristics are provided in Additional file 1: Appendix 2. Six studies examined induction and maintenance phase treatments (19 %), four maintenance phase treatments (13 %), and the rest induction phase treatments (68 %) only. Nine were open-label RCTs and two were quasi-RCTs. Study sample size ranged from 15 to 370. Most studies included patients with diffuse glomerulonephritis and/or membranous glomerulonephritis (Additional file 1: Appendix 2). Studies were mostly single site studies except for nine studies (28 %) that were multicenter. The majority of the patients in the included studies were female. The risk of bias was low for most criteria and unclear for some criteria (Additional file 1: Appendix 3).

The network for serious infections contained multiple treatments as well as sequential and combination regimens (Fig. 2). As expected, most studies compared MMF and high-dose CYC. The network had several direct comparisons of various medications and regimens to each other. These studies included 2611 patients who had 332 serious infections (Additional file 1: Appendix 4). Of these studies, 26 were two-arm, five three-arm, and one four-arm, and these studies included 14 different treatments (Table 1). Six out of 32 studies had at least one arm with zero events. None of the included studies had all arms with zero events (Additional file 1: Appendix 4). The number of serious infections for each of the comparisons (numerator) and the total number of patients available (denominator) is shown in Additional file 1: Appendix 5.

**Comparison of immunosuppressive drugs with glucocorticoids**

Eleven studies provided data for these comparisons. Crude rates of serious infections with immunosuppressive drugs and glucocorticoids showed the highest crude serious infection rate with high-dose glucocorticoids at 26.7 % (one study only); rates were 15.1 % and 11.6 % with CYC and MMF, respectively (Table 1). Crude rates for serious infections with other treatments are shown in Table 1.

We found that tacrolimus was associated with significantly lower risk of serious infections compared to standard-dose corticosteroid, with an OR of 0.33 (95 % CrI, 0.12–0.88) (Table 2). We also found that MMF-AZA (MMF followed by AZA) was associated with significantly lower risk of serious infections as compared to high-dose glucocorticoids, with a relative risk of 0.03 (95 % CrI, 0.00–0.56) (Table 2). Other differences comparing immunosuppressive drugs to glucocorticoids or high-dose glucocorticoids did not reach statistical significance (Fig. 3).

**Comparison of immunosuppressive drugs with each other**

Twenty-three studies provided data for these comparisons (three studies provided data for both comparisons). Crude rates of serious infections are shown in Table 1, ranging 8.7 % for TAC to 20.6 % with CYC-AZA, for treatments with more than one study. TAC was associated with significantly lower risk of serious infections compared to CYC, MMF, and AZA, with ORs of 0.37, 0.40, and 0.32, respectively (Table 2). We also found that MMF-AZA (MMF followed by AZA) was associated with significantly lower odds of serious infections as compared to low-dose CYC, high-dose CYC, and CYC-AZA with ORs of 0.09, 0.07, and 0.14, respectively (Table 2).

The staircase diagrams show the ORs for the comparisons of treatments where at least one comparison was significant (Fig. 3). With the exception of the differences discussed in the two sections above, other differences did not reach statistical significance (Fig. 3). In order to check the consistency of the NMA results, we conducted the inconsistency analysis and compared with our consistent NMA results (Fig. 4). Based on this comparison between two models, only three points had a higher than expected posterior mean difference (Fig. 4). Most parameter estimates are very similar between two models. For
the overall NMA, the tau (reciprocal of variance between-study; a measure of heterogeneity) was 26.39, and the standard deviation was 0.1949, which is less than 0.5, indicating that heterogeneity is low. We noted some inconsistency of parameter estimates; however, sensitivity analysis that evaluated the results with and without those studies showed that parameter estimates (effects estimates, standard error, etc.) are mostly similar and showed no change on interpretation of the results and conclusions.

Comparison of NMA results to direct estimates from meta-analyses for main findings

We compared the results from our NMA to traditional pair-wise meta-analyses, where this was possible, TAC versus MMF and TAC versus CYC. The robustness of estimates was indicated by minimal/no differences in estimates between the NMA and the meta-analyses (TAC vs. MMF, 0.40 vs. 0.42; and TAC vs. CYC, 0.37 vs. 0.28, respectively; Additional file 1: Appendix 6). Heterogeneity, as measured by I-squared, was 0 % for TAC versus MMF and 0 % for TAC versus CYC for direct comparisons by meta-analyses. The GRADE quality of evidence was moderate for direct comparison with meta-analyses and moderate for NMA estimates, downgraded for imprecision in both cases.

Sensitivity analyses

We undertook multiple sensitivity analyses to test the robustness of our study findings. Sensitivity analyses by using the random effects versus fixed effects models (Table 3) or by the type of method used for estimation (OR vs. Peto’s OR) (Fig. 5) revealed no change in interpretation and minimal change in estimates.

Replacing sepsis events (included in serious infection definition) by serious infections in the Appel et al. [31] study revealed slight differences in the significance of MMF-AZA versus low-dose CYC, high-dose glucocorticoids, and high-dose CYC comparisons, i.e., these differences were no longer statistically significant; other
Table 1: Crude rates of serious infections with immunosuppressive drugs or corticosteroids in patients with lupus nephritis

| Treatment       | #Studies | # Events | # Patients | Aggregate rate, per patient | Minimum rate | Maximum rate |
|-----------------|----------|----------|------------|-----------------------------|--------------|--------------|
| Glucocorticoids | 10       | 30       | 179        | 0.181                       | 0.106        | 0.291        |
| CYC             | 12       | 46       | 285        | 0.151                       | 0.092        | 0.240        |
| MMF             | 12       | 69       | 728        | 0.116                       | 0.072        | 0.182        |
| AZA             | 8        | 45       | 266        | 0.184                       | 0.095        | 0.329        |
| TAC             | 5        | 14       | 171        | 0.087                       | 0.052        | 0.141        |
| CSA             | 3        | 10       | 65         | 0.166                       | 0.091        | 0.283        |
| CYC LD          | 4        | 21       | 128        | 0.172                       | 0.114        | 0.252        |
| HD glucocorticoids | 1      | 4        | 15         | 0.267                       | 0.104        | 0.533        |
| CYC HD          | 9        | 60       | 506        | 0.131                       | 0.073        | 0.225        |
| AZA HD          | 1        | 2        | 20         | 0.100                       | 0.00         | 1.131        |
| LEF HD          | 1        | 3        | 70         | 0.043                       | 0.00         | 0.090        |
| CYC-AZA         | 3        | 15       | 74         | 0.206                       | 0.118        | 0.333        |
| MMF-AZA         | 1        | 2        | 32         | 0.063                       | 0.00         | 0.146        |
| RTX + MMF       | 1        | 12       | 72         | 0.167                       | 0.081        | 0.253        |

CYC-AZA: CYC followed by AZA
MMF-AZA: MMF followed by AZA
RTX + MMF, RTX combined with MMF
CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC tacrolimus, CSA cyclosporine, LEF leflunomide, HD high dose, LD low dose; when not specified, standard dose should be inferred

Table 2: Serious infection risk in patients with lupus nephritis with various immunosuppressive drugs or corticosteroids showing only the statistically significant results

| Treatment       | Reference       | OR (95 % CrI) | RR (95 % CrI) | RD (95 % CrI) |
|-----------------|-----------------|---------------|---------------|---------------|
| TAC             | Glucocorticoids | 0.33 (0.12–0.88) | 0.36 (0.14–0.90) | –0.09 (–0.15 to –0.01) |
| TAC             | CYC             | 0.37 (0.15–0.87) | 0.41 (0.17–0.88) | –0.07 (–0.14 to –0.01) |
| TAC             | MMF             | 0.40 (0.18–0.81) | 0.43 (0.21–0.83) | –0.07 (–0.14 to –0.02) |
| TAC             | AZA             | 0.32 (0.12–0.81) | 0.35 (0.14–0.83) | –0.09 (–0.20 to –0.02) |
| CYC LD          | TAC             | 4.84 (1.48–17.64) | 4.00 (1.43–11.47) | 0.15 (0.03 to 0.40) |
| HD glucocorticoids | TAC           | 12.83 (1.53–119.90) | 7.67 (1.47–25.14) | 0.35 (0.03 to 0.79) |
| CYC HD          | TAC             | 6.60 (2.25–20.50) | 5.06 (2.03–12.89) | 0.20 (0.07 to 0.43) |
| MMF-AZA         | CYC LD          | 0.09 (0.01–0.76) | 0.11 (0.01–0.79) | –0.17 (–0.43 to –0.03) |
| MMF-AZA         | HD glucocorticoids | 0.03 (0.00–0.56) | 0.06 (0.00–0.61) | –0.37 (–0.82 to –0.04) |
| MMF-AZA         | CYC HD          | 0.07 (0.01–0.54) | 0.09 (0.01–0.60) | –0.22 (–0.46 to –0.06) |
| MMF-AZA         | CYC-AZA         | 0.14 (0.02–0.71) | 0.16 (0.02–0.75) | –0.11 (–0.29 to –0.02) |

All odds ratios are statistically significant

Glucocorticoids were defined as one of the following or a similar regimen: (1) prednisone or methylprednisolone 1 gm/m² qd intravenous × 3 at entry, then one dose intravenous q month for 1 year; (2) prednisone 1 mg/kg po qd with a slow taper up to 1 year or longer taper (or unspecified taper in an occasional case)

High-dose (HD) glucocorticoids were defined as one of the following or a similar regimen: (1) prednisone or methylprednisolone 1 gm/m² qd intravenous × 3 at entry, then one dose intravenous q month for 1 year; (2) prednisone 1 mg/kg po qd with a slow taper up to 1 year or longer taper (or unspecified taper in an occasional case)

Low-dose (LD) cytosporine, MMF mycophenolate mofetil, AZA azathioprine, TAC tacrolimus, HD high dose, LD low dose; when not specified, standard dose should be inferred

This table shows the serious infection risk in patients with lupus nephritis with various immunosuppressive drugs or corticosteroids, highlighting only the statistically significant results.
comparisons did not change in estimates or significance (Additional file 1: Appendix 7). When we further excluded two studies with observational data [33, 34] from the dataset with serious infection data from Appel et al. [31], we noted no change in estimates or significance except that CYC-AZA versus TAC now became significant, 3.37 (0.75–15.56) versus 14.13 (1.07–220.2), although the confidence intervals were wide (Additional file 1: Appendix 8).

When we combined CYC and high-dose CYC, most associations did not change, except that one MMF-AZA comparison became significant in the combined analyses compared to previously: versus CYC (0.11 (0.01–0.91); Additional file 1: Appendix 9).

Sensitivity analyses based on different priors were performed. The parameter estimates were consistent with these different priors to the main analysis (Additional file 1: Appendix 10). The model fit criteria, such as DIC and residual deviance, were also similar with those priors (Additional file 1: Appendix 10).

**Subgroup analysis**

Comparison of studies before and after 2004 was performed considering potential change in management after the publication of the Contreras et al. [29] study in the *New England Journal of Medicine*. For most comparisons, the studies fell into one of the two periods, allowing no meaningful interpretation of results for any time-period effect (Additional file 1: Appendix 11). Since we divided the studies into two time-periods, the network was smaller and 95 % confidence intervals wider and more imprecise with this subgroup analysis. We could not perform subgroup analyses by age, gender, race, and prior immunosuppressive therapy due to lack of enough data presented by these characteristics in the included studies.

**Discussion**

In our systematic review and network meta-analyses (NMA), we included a large number of studies and
compared the risk of serious infections in patients with
lupus nephritis who were treated with immunosuppres-
sive drugs and/or glucocorticoids. We performed a
NMA that incorporated indirect and direct comparisons
and allowed us to compare several treatments to each
other. Importantly, for most of the comparisons, we also
had direct comparison trials. We performed several sen-
sitivity analyses and most of these confirmed the robust-
ness of the findings. Several study findings merit further
discussion.

We found that TAC was associated with lower risk of
serious infections compared to several other immunosup-
pressive drugs and to standard-dose glucocorticoids.
Specifically, compared to CYC, MMF, AZA, and standard-
dose glucocorticoids, TAC was associated with one-third
the odds of serious infections. High-dose CYC and high-
dose glucocorticoids were associated with 7–15 times
higher odds of serious infections compared to TAC, pro-
viding some evidence for dose-response, with odds going
from three-fold for standard dose to 7- to 15-fold for high
dose. These are new findings to our knowledge and were
robust in multiple sensitivity analyses. Sensitivity analyses
we performed, included the following: (1) random or fixed
effects model; (2) pair-wise meta-analyses versus NMA;
(3) OR versus Peto’s OR for estimation; (4) the use of
sepsis versus serious infection data from Appel et al. [31];
(5) exclusion of data from two observational studies
previously included in the 2012 Cochrane review versus
inclusion of all studies; and (6) comparing to CYC and
high-dose CYC in a combined treatment group versus the
treatments separately. Thus, the risk of serious infections
seems to be less with TAC compared to most comparable
immunosuppressive regimens. This finding is similar to
that of a large trial in nephrotic syndrome in children,

Table 3  Sensitivity analyses by random versus fixed effects for
serious infection risk by comparison of significant estimates
between random and fixed effects models

| Comparison | Random effects model | Fixed effects model |
|------------|----------------------|---------------------|
|            | Odds ratio (95 % CrI) | Odds ratio (95 % CrI) |
| TAC vs. glucocorticoids | 0.33 (0.12–0.88) | 0.33 (0.13–0.82) |
| TAC vs. CYC | 0.37 (0.15–0.87) | 0.37 (0.16–0.82) |
| TAC vs. MMF | 0.40 (0.18–0.81) | 0.40 (0.20–0.78) |
| TAC vs. AZA | 0.32 (0.12–0.81) | 0.32 (0.13–0.77) |
| CYC LD vs. TAC | 4.84 (1.48–17.64) | 4.50 (1.43–14.50) |
| HD glucocorticoids vs. TAC | 12.83 (1.53–119.90) | 12.22 (1.58–105.70) |
| CYC HD vs. TAC | 6.60 (2.25–20.50) | 6.52 (2.38–18.95) |
| MMF-AZA vs. CYC LD | 0.09 (0.01–0.76) | 0.09 (0.01–0.74) |
| MMF-AZA vs. HD glucocorticoids | 0.03 (0.00–0.56) | 0.21 (0.02–1.79) |
| MMF-AZA vs. CYC HD | 0.07 (0.01–0.54) | 0.07 (0.01–0.47) |
| MMF-AZA vs. CYC-AZA | 0.14 (0.02–0.71) | 0.14 (0.02–0.65) |
| Residual deviance | 72.49 | 74.9 |
| Number of unconstrained data points | 71 | 71 |
| Deviance information criteria | 325.646 | 325.51 |

All odds ratios are statistically significant
Odds ratios from either model are very similar to each other, denoting the
robustness of the analyses, regardless of assumptions
CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC
tacrolimus, HD high dose, LD low dose; when not specified, standard dose
should be inferred

Fig. 4  The figure shows the deviances from consistency and the inconsistence models. Consistency model assumes that the evidence derived
from direct and indirect estimates should be in agreement. The inconsistence model does not make this assumption. Ideally, all deviances
should be 2 or below. There were 71 unconstrained data points. Three data points show deviances of > 2 (extreme right side in the figure).
Residual deviances from consistency versus inconsistence models were 72.49 versus 67.73 for 69 data points each. Deviance information
criteria was 325.65 versus 325.96, respectively, indicating that the inconsistence model is a slightly better fit for the data than the consistency
model. Thus, the model showed some evidence of inconsistence
where 4/66 TAC- versus 16/65 CYC-treated patients had serious infections [35]. In a recent systematic review and meta-analysis of TAC for lupus nephritis, TAC (alone or in combination with MMF) was more efficacious than intravenous CYC and as efficacious as MMF for complete or partial renal remission [36]. The review also reported slight mortality advantage with TAC versus controls [36]. Our study finding of lower rate of serious infections, in conjunction with superiority over a previously commonly used therapy (intravenous CYC) might partially explain mortality benefit with TAC.

We did not notice any systematic differences in study populations or the stage of lupus nephritis between trials of TAC versus other immunosuppressive medications. Use of a lower start dose of TAC and titration to achieve trough serum levels may have led to a smaller cumulative TAC dose versus comparators. All included TAC trials were of small sample size and performed in China (non-Caucasian), not unlike several trials for other medications, which were performed internationally.

This information regarding the comparative risk of serious infections with various immunosuppressive drugs in lupus nephritis can be helpful in conjunction with comparative efficacy data that can empower patients to explicitly weigh comparative risks and benefits. These data can be effectively used for informed decision-making by patients with lupus nephritis, in general, but particularly in patients with recurrent infections/serious infections or in those with high-risk comorbidities that increase the risk of serious infections. Compared to Whites, minorities have higher incidence and prevalence of lupus nephritis [37, 38], more severe disease and worse outcomes [39, 40], and more than three times higher mortality [41, 42]. The reasons for these worse outcomes in minorities are not clear, but may be partially related to health access barriers, socioeconomic differences, and higher use of glucocorticoids alone versus immunosuppressives plus glucocorticoids. Future studies need to examine whether the risk difference in serious infections with various medications varies by race/ethnicity.

On the other, we found no significant differences between MMF and CYC for serious infection risk, an important study finding. The OR for serious infection with MMF versus CYC was 0.98 (95 % CI, 0.50–1.95) in our study, which included 32 studies and was statistically not significant. This is an area of great interest and debate since MMF and CYC are among the most common immunosuppressive drugs used for the treatment of lupus nephritis. In a meta-analysis published in 2007 that included five RCTs with 307 patients [29], MMF was associated with a risk ratio of 0.65 (96 % CI, 0.51–0.82; P < 0.001) of overall infections compared with CYC [9]. The most comprehensive study to date, the 2012 Cochrane systematic review that included six studies [31] with infection data for 683 patients (total of 50 studies with 2846 patients included) [10], showed that MMF was not associated with any increase in the risk of major infections (defined as all-cause infections other than herpes zoster) compared to intravenous CYC, and the relative risk was 1.11 (95 % CI, 0.74–1.68) [10]. Our systematic review, meta-analysis, and NMA findings support the earlier finding from the Cochrane systematic review that a difference in the risk of serious infection risk between CYC and MMF was not evident.

However, MMF-AZA was associated with lower odds of serious infections compared to CYC-AZA, high-dose CYC, low-dose CYC, and high-dose glucocorticoids, indicating that some differences may exist between MMF and CYC when followed by AZA. We need data from longer-term studies or studies with a larger sample size. It also remains to be seen whether the EURO-lupus CYC dose (low dose) is a safer option than the regular CYC regimen, especially with regards to the risk of serious infections. This is an
important consideration for future studies of harms, since CYC can be given in more than one dose, and most previous analyses have not accounted for CYC dose.

Another important aspect of serious infection risk is the contribution of glucocorticoids to this risk, since they are often used concomitantly with immunosuppressive drugs. A previous meta-analysis of 25 RCTs showed that this risk of major infection did not increase by combining immunosuppressive drugs with glucocorticoids for lupus nephritis treatment, namely, the risk did not differ between CYC or AZA plus glucocorticoids versus glucocorticoids alone [8]. On the other hand the renal-protective benefits of combining immunosuppressive drugs with glucocorticoids for induction therapy have been clearly demonstrated decades ago by an NIH study [43]. Studies that can carefully measure and control for corticosteroid use might help to delineate the contributions they make to serious infection risk when used concomitantly with immunosuppressive drugs. Since our analyses include RCTs, among patients randomized to one of the immunosuppressive drugs, corticosteroid use should be similar except when corticosteroid is used in only one of the treatment arms. Rituximab is an emerging treatment for lupus nephritis with some controversy regarding its efficacy. Our systematic review included only one study with RTX versus placebo in patients receiving MMF and glucocorticoids for lupus nephritis, and no differences were noted in the risk of serious infections versus other medications, including TAC. More data are needed to define its role in the treatment of lupus nephritis.

Study strengths are the use of state-of-the-art systematic review and NMA methodology, the use of large number of trials (and patients) in the analyses, robustness of estimates as demonstrated by no/minimal change in estimates with sensitivity analyses, robustness with models using different priors, and the concordance of findings from NMA with that from traditional pair-wise meta-analyses. The overall quality of evidence for the main findings was moderate, which must be considered while interpreting study results.

Our study has several limitations. Study population heterogeneity between included trials can lead to observations of differences between them, which may be attributable to differences in the types of patients being treated rather than the type of medication being used. In our view, most RCTs were more similar than different, since they enrolled patients with diffuse glomerulonephritis with very few focused on membranous nephropathy and most RCTs were induction or induction/maintenance. While some trials lasted several years, most were 6 months long and the number of patients was less than 100 for the majority of the trials. This leads to small sample sizes and, in cases of rare events such as serious infections, a small number of patients having the outcome. This can lead to suboptimal power to detect all clinically relevant differences between medications, i.e., type II error. We may have missed some differences due to low power. We performed a lot of comparisons, which could have also led to observed significance of some differences just by chance, i.e., type I error. We think this (type I error) is less likely given the rarity of serious infection outcome and our main concern is missing important differences due to the few number of events (type II error). This means that future NMAs in this area will greatly benefit from the addition of new large studies. We limited the search to the English language. Exclusion of studies in non-English language and other databases may have led to missing some pertinent studies. Publication bias assessment was planned (funnel plot), but could not be done due to the lack of treatment pairs with more than 10 studies.

Conclusions
In summary, we found that tacrolimus was associated with a lower risk of serious infections compared to other immunosuppressives or glucocorticoids. Similar observations were also noted for MMF-AZA. Our systematic review and NMA provides a state-of-the-art analyses of the risk of serious infections with immunosuppressives and glucocorticoids. The overall quality of evidence was moderate. This study provides data that can be used during discussions with patients to better inform them of the comparative risks with various treatment options for lupus nephritis. The results of these analyses will be used in developing a patient decision aid, which will be tested in a randomized trial.

Additional file

Additional file 1: Additional Files summarizing details of studies includes and sensitivity analyses. (DOCX 117 kb)

Abbreviations
AZA, azathioprine; Crl, credible interval; CSA, cyclosporine; CYC, cyclophosphamide; DIC, deviance information criteria; MMF, mycophenolate mofetil; MTC, mixed treatment comparison; NMA, network meta-analysis; OR, odds ratios; RCTs, randomized controlled trials; RTX, rituximab; TAC, tacrolimus.

Acknowledgements
We thank the three librarians, Tamara Roder from the Cochrane Collaboration, Janet Joyce from the American College of Rheumatology, and Carolyn Holmes from the University of Alabama at Birmingham, for performing the literature searches. We thank Aseem Bharat and Ana Oliveira for screening titles and abstracting data. We thank Dr. Nipam Shah, University of Alabama at Birmingham, for a careful review of the final manuscript and editing and checking the accuracy of numbers compared to results of the analyses. We thank Amy Mudano, MPH, University of Alabama at Birmingham, for help with data programming for the analyses.

Funding
This research was made possible by a Grant from the Patient Centered Outcomes Research Institute (PCORI; Grant Number CE-1304-6631) and its contents are solely the responsibility of the authors and do not necessarily...
represent the official views of the PCORI. JAS was also supported by resources and the use of facilities at the VA Medical Center at Birmingham, Alabama.

**Availability of data and materials**
Not applicable.

**Authors’ contributions**
JS and GW designed the study; JS wrote the protocol; GW, AH and AK provided comments on the protocol. AH and AK performed the data analyses. All authors reviewed the analyses results and provided feedback related to the analyses. JS wrote the first draft of the paper. All authors edited and revised the manuscript and approved the final version for submission.

**Competing interests**
JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Bioiberica, Crealta, and Allergan pharmaceuticals, WebMD, UBM LLC, and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity and is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee; Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. AH and AK have no financial conflicts to declare. GW has received research grant and consultant fees from Bristol-Myers Squibb, consultant fees from Abbott, Amgen, and UCB, and is a data safety monitor for Novartis.

**Consent for publication**
Not applicable.

**Ethical approval and consent to participate**
The University of Alabama at Birmingham’s Institutional Review Board approved this study and all investigations were conducted in conformity with ethical principles of research. The ethics committee waived the need for informed patient consent for this part of the study that involved analyzing published group-level trial data in public domain.

**Author details**
1. Medicine Service, VA Medical Center, Birmingham, AL 35233, USA.
2. Department of Medicine at the School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
3. Division of Epidemiology at the School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
4. Department of Orthopaedic Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
5. Ottawa Heart Institute and the University of Ottawa, Ottawa, Ontario K1Y 4W7, Canada.

**Received:** 10 February 2016 **Accepted:** 10 August 2016 **Published online:** 13 September 2016

**References**
1. Schwartz N, Goidiev L, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26(5):502–9.
2. Houssiau FA, Lauwers BR. Current management of lupus nephritis. Best Pract Res Clin Rheumatol. 2012;26(3):319–28.
3. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz MB, Fontin PR, Petri M, Barr S, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–7.
4. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalińska-Sadowska H, de Ramon E, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2008;87(2):299–308.
5. Garcia-Pop-Lisseau MG, Greisinger A, Richardson M, O’alley KJ, Jansen NM, Marcus DM, Tagore J, Suarez-Almazor ME. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913–9.
6. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266–71.
7. Kumar K, Gordon C, Barry R, Shaw K, Horne R, Raza K. It’s like taking poison to kill poison but I have to get better. A qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837–44.
8. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2004;43(2):197–208.
9. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22(7):1933–42.
10. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74–87.
11. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC. Treatment for lupus nephritis. Cochrane Database Syst Rev. 2012;12:CD002022.
12. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313–24.
13. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. http://effectivecare.healthcare.gov/index.cfm/search-for-guides-reviews-and-reports?Pageaction&displayProducts&productId=318. Accessed 23 Aug 2016.
14. Blencourt DC, Pinheiro CC, Malafonte P, Titan S, de Alves BG, Gea AJ, Dos SS, Porto BR, Woronik V. Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. Clin Nephrol. 2011;76(1):517–63.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
16. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
17. Singh JA, Noorbalooci S, Tucker MD. Belimumab for systemic lupus erythematosus (protocol). Cochrane Database Syst Rev. 2013. doi:10.1002/14651858.CD010668.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
19. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1.0 (updated March 2011). In: Higgins J, Green S, editors. The Cochrane Collaboration. 2011. Available from http://handbook.cochrane.org/.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
21. Dias S, Sutton A, Welton N, Ades A, Golfinopoulos V, Kjągjou M, et al. NICE DSU Technical Support Document 2: Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. Sheffield: Decision Support Unit SchARR; 2011. p. 1–96.
22. Dias S, Sutton A, Welton N, Ades A, Golfinopoulos V, Kyngjou M, et al. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, meta-regression, bias and bias-adjustment. Sheffield: Decision Support Unit SchARR; 2011. p. 1–24.
23. Cooper NJ, Sutton AJ, Morris D, Ades A, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14):1861–81.
24. Turner RM, Thompson SG, Spiegelhalter D. Prior distributions for the intraclass correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials. Clin Trials. 2005;2(2):108–18.
25. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual. Version 1.4. Cambridge: BUGS Project, 2003.
26. Ades AE, Welton NJ, Caldwell D, Price M, Goubau A, Lu G. Multivariate evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy. 2008;13 Suppl 3:12–22.
27. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modelling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17.
28. Dias S, Sutton A, Welton N, Ades A, Golfinopoulos V, Kyrgiou M, et al. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. Sheffield: Decision Support Unit Scharr; 2011. p. 1–39.

29. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(10):971–80.

30. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.

31. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysteller E, Sanchez-Guerrero J, Solomons N, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12.

32. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41(3):818–27.

33. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis. 2001;38(2):256–64.

34. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008;17(7):638–44.

35. Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, Mantan M, Agarwal I, Dinda AK, Hari P, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1310–5.

36. Hannah J, Casisan A, D'Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev. 2016;15(1):93–101.

37. Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH. Medication nonadherence is associated with increased subsequent acute care utilization among medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res. 2015;67(12):1712–21.

38. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, Winkelmann WC, Costenbader KH. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753–63.

39. Odutola J, Ward MM. Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Curr Opin Rheumatol. 2005;17(2):147–52.

40. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, McGwin Jr G, Bartolucci AA, Roseman JM, Reveille JD. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in Minority populations: NAture vs. Nurture. Lupus. 1999;8(3):197–209.

41. Centers for Disease Control and Prevention (CDC). Trends in deaths from systemic lupus erythematosus–United States, 1979–1998. MMWR Morb Mortal Wkly Rep. 2002;51(17):371–4.

42. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006;65(11):1500–5.

43. Boumpas DT, Austin 3rd HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741–5.